Dubai, 22nd April 2015
Genpharm and Admedus announced an agreement on the commercialization of CardioCel®. Under the terms of the agreement Genpharm acquires exclusive right to commercialize the compound in MENA region.
Commenting on the agreement, Karim Smaira, Genpharm managin partner said “We feel excited to partner with Admedus in bringing CardioCel to the MENA region for the repair of heart defects in both children and adult patients. We are both committed to improving the quality of life for these patients”.
“Admedus is highly strategic in the selection and appointment of specialist distributors in regions where we do not have a direct sales force. This forms an important part of our global launch strategy for CardioCel” said Admedus CEO Mr. Lee Rodne. “Genpharm has a strong reputation and presence in the region and we look forward to broadening CardioCel®’s availability globally.”
To read the full press release click here.